Literature DB >> 9076906

Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane.

M E Peterson1, P P Kintzer.   

Abstract

Mitotane (o,p'-DDD; Lysodren) is the drug most commonly used to treat dogs with pituitary-dependent hyperadrenocorticism. Although variations of the original protocol, suggested more than 20 years ago, have been reported, most clinicians still use an initial loading dose of mitotane followed by a weekly maintenance dose. Although a gratifying response to treatment is seen in most dogs, some dogs are neither easy nor straightforward to treat and present the practitioner with one or more therapeutic challenges, including failure to respond adequately, development of adverse effects, or development of relapse during treatment. Nevertheless, with careful management and follow-up, such problems can be overcome and a successful outcome achieved in most cases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9076906     DOI: 10.1016/s0195-5616(97)50030-1

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  6 in total

Review 1.  Alopecia: possible causes and treatments, particularly in captive nonhuman primates.

Authors:  Melinda A Novak; Jerrold S Meyer
Journal:  Comp Med       Date:  2009-02       Impact factor: 0.982

Review 2.  Canine hypoadrenocorticism: part I.

Authors:  Susan C Klein; Mark E Peterson
Journal:  Can Vet J       Date:  2010-01       Impact factor: 1.008

3.  Differential relationships between chronic hormone profiles in pregnancy and maternal investment in rhesus monkey mothers with hair loss in the neonatal period.

Authors:  Amanda M Dettmer; Kendra Rosenberg; Mark T Menard; Saif N El-Mallah; Ruth A Woodward; Stephen J Suomi; Jerrold S Meyer
Journal:  Am J Primatol       Date:  2015-10-23       Impact factor: 2.371

4.  Carbenoxolone Disodium Treatment for Canine Pituitary-Dependent Hyperadrenocorticism.

Authors:  Takahiro Teshima; Hirotaka Matsumoto; Tomoko Okusa; Rion Uchiyama; Hidekazu Koyama
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

5.  Mitotane (o,p'-DDD) treatment in a cat with hyperadrenocorticism.

Authors:  C S Schwedes
Journal:  J Small Anim Pract       Date:  1997-11       Impact factor: 1.522

6.  Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis.

Authors:  Takahiro Teshima; Hirotaka Matsumoto; Tomoko Okusa; Yumi Nakamura; Hidekazu Koyama
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.